Spots Global Cancer Trial Database for juvenile myelomonocytic leukemia
Every month we try and update this database with for juvenile myelomonocytic leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT | NCT03810196 | Acute Leukemia Acute Myeloid L... Myelodysplastic... Acute Lymphobla... Mixed Lineage L... Lymphoblastic L... Burkitt Lymphom... Juvenile Myelom... | CliniMACS Cell ... | - 25 Years | Children's Hospital of Philadelphia | |
| Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia | NCT01824693 | Juvenile Myelom... | Allogeneic Hema... Busulfan Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Melphalan Mycophenolate M... Pharmacological... Tacrolimus | 3 Months - 18 Years | Children's Oncology Group | |
| Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML) | NCT02447666 | Myelodysplastic... Leukemia, Myelo... | Azacitidine | 1 Month - 18 Years | Celgene | |
| Myeloablative Haploidentical BMT With Post-transplant Cyclophosphamide for Pediatric Patients With Hematologic Malignancies | NCT02120157 | Myeloablative C... HLA-mismatched ... Graft Survival Transplantation... | Cyclophosphamid... TBI Busulfan Unmanipulated B... Tacrolimus Mycophenolate m... | 6 Months - 25 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Stem Cell Transplantation for Patients With Hematologic Malignancies | NCT00152139 | Acute Lymphobla... Acute Myelocyti... Chronic Myeloid... Juvenile Myelom... Myelodysplastic... Hemoglobinuria,... Non-Hodgkin Lym... | Allogeneic Stem... Chemotherapy an... | 2 Years - 21 Years | St. Jude Children's Research Hospital | |
| Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders | NCT03314974 | Acute Leukemia Acute Myeloid L... Acute Lymphobla... Lymphoma Chronic Myeloge... Plasma Cell Leu... Myeloproliferat... Myelofibrosis Myelodysplasia Refractory Anem... High Risk Anemi... Chronic Lymphoc... Small Lymphocyt... Marginal Zone B... Follicular Lymp... Lymphoplasmacyt... Mantle-Cell Lym... Prolymphocytic ... Diffuse Large C... Lymphoblastic L... Burkitt Lymphom... High Grade Non-... Multiple Myelom... Juvenile Myelom... Biphenotypic/Un... MRD Positive Le... Natural Killer ... Acquired Bone M... | HSCT with TBI R... HSCT with Non-T... | - 60 Years | Masonic Cancer Center, University of Minnesota | |
| Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation | NCT03843528 | Acute Myeloid L... Myelodysplastic... Mixed Phenotype... Juvenile Myelom... | Vorinostat Azacitidine Inj... | 1 Year - 21 Years | Johns Hopkins All Children's Hospital | |
| Stem Cell Transplantation for Patients With Hematologic Malignancies | NCT00152139 | Acute Lymphobla... Acute Myelocyti... Chronic Myeloid... Juvenile Myelom... Myelodysplastic... Hemoglobinuria,... Non-Hodgkin Lym... | Allogeneic Stem... Chemotherapy an... | 2 Years - 21 Years | St. Jude Children's Research Hospital | |
| Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases | NCT05800210 | Acute Lymphobla... Acute Myeloid L... Juvenile Myelom... Myelodysplastic... Chronic Myeloid... Lymphoma, Non-H... Lymphoma, Hodgk... | Miltenyi CliniM... | 6 Months - 39 Years | University of Florida | |
| Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation | NCT03843528 | Acute Myeloid L... Myelodysplastic... Mixed Phenotype... Juvenile Myelom... | Vorinostat Azacitidine Inj... | 1 Year - 21 Years | Johns Hopkins All Children's Hospital | |
| Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders | NCT03314974 | Acute Leukemia Acute Myeloid L... Acute Lymphobla... Lymphoma Chronic Myeloge... Plasma Cell Leu... Myeloproliferat... Myelofibrosis Myelodysplasia Refractory Anem... High Risk Anemi... Chronic Lymphoc... Small Lymphocyt... Marginal Zone B... Follicular Lymp... Lymphoplasmacyt... Mantle-Cell Lym... Prolymphocytic ... Diffuse Large C... Lymphoblastic L... Burkitt Lymphom... High Grade Non-... Multiple Myelom... Juvenile Myelom... Biphenotypic/Un... MRD Positive Le... Natural Killer ... Acquired Bone M... | HSCT with TBI R... HSCT with Non-T... | - 60 Years | Masonic Cancer Center, University of Minnesota | |
| Quality of Life of Adult Cancer Survivors Who Have Undergone a Previous Bone Marrow or Peripheral Stem Cell Transplant for a Childhood Hematologic Cancer | NCT00126477 | Leukemia Lymphoma Myelodysplastic... Quality of Life | cognitive asses... management of t... psychosocial as... quality-of-life... | 18 Years - | Fred Hutchinson Cancer Center | |
| Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML | NCT00669890 | Acute Myeloid L... Juvenile Myelom... Myelodysplastic... | Gemtuzumab Ozog... Busulfan Cyclophosphamid... Thymoglobulin Tacrolimus Mycophenolate M... Methotrexate | - 30 Years | New York Medical College | |
| Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation | NCT02458235 | Acute Myelogeno... Acute Lymphoid ... Juvenile Myelom... Myelodysplastic... | azacitidine donor lymphocyt... | - 29 Years | University of California, San Francisco | |
| Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases | NCT00450450 | Childhood Acute... Childhood Acute... Childhood Chron... Childhood Myelo... Chronic Phase C... de Novo Myelody... Juvenile Myelom... Previously Trea... Recurrent Child... Secondary Myelo... | allogeneic bone... laboratory biom... filgrastim | - 21 Years | Children's Oncology Group | |
| Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia | NCT01445080 | Blastic Phase Childhood Acute... Childhood Chron... Childhood Solid... Chronic Myeloge... Juvenile Myelom... Philadelphia Ch... Recurrent Child... Recurrent Child... Recurrent Disea... | Laboratory Biom... Pharmacological... Sorafenib Tosyl... | 2 Years - 21 Years | National Cancer Institute (NCI) | |
| Donor Stem Cell Transplant in Treating Young Patients With Myelodysplastic Syndrome, Leukemia, Bone Marrow Failure Syndrome, or Severe Immunodeficiency Disease | NCT00295971 | Congenital Ameg... Leukemia Myelodysplastic... Severe Congenit... | anti-thymocyte ... therapeutic all... fludarabine pho... thiotepa allogeneic bone... allogeneic hema... in vitro-treate... total-body irra... | 1 Year - 17 Years | University of California, San Francisco | |
| Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer | NCT00898079 | Acute Undiffere... Atypical Chroni... Childhood Acute... Childhood Acute... Childhood Chron... Childhood Solid... Chronic Lymphoc... Hairy Cell Leuk... Juvenile Myelom... Mast Cell Leuke... Neoplasm of Unc... Prolymphocytic ... Secondary Acute... T-Cell Large Gr... | Cytology Specim... | - 30 Years | Children's Oncology Group | |
| Etanercept (Enbrel) for Juvenile Myelomonocytic Leukemia | NCT00509600 | Leukemia | Etanercept | 6 Months - 18 Years | M.D. Anderson Cancer Center | |
| Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies | NCT00697671 | Acute Lymphobla... Chronic Myeloge... Juvenile Myelom... Myelodysplastic... Non-Hodgkin's L... | NK Cell Infusio... Immunotherapy Miltenyi Biotec... Interleukin-2 (... Clofarabine Cyclophosphamid... Etoposide | - 18 Years | St. Jude Children's Research Hospital | |
| A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies | NCT01036009 | Acute Leukemia Acute Myeloid L... Acute Lymphobla... Biphenotypic Le... Pre-leukemic Sy... Monosomy 7 Bone Marrow Clo... Juvenile Myelom... Myelodysplastic... Chronic Myeloge... | Withdrawal of i... | 6 Months - 25 Years | University of California, San Francisco | |
| Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation | NCT00609739 | Leukemia | cyclosporine cytarabine filgrastim methotrexate methylprednisol... mitoxantrone hy... allogeneic bone... umbilical cord ... Cis-Retinoic ac... | - 18 Years | Masonic Cancer Center, University of Minnesota | |
| Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS) | NCT02564536 | Chronic Myelomo... Juvenile Myelom... Atypical Chroni... Myeloproliferat... Myelodysplastic... Myelofibrosis | Pacritinib Decitabine | 18 Years - | Washington University School of Medicine | |
| Tipifarnib in Treating Young Patients With Refractory Leukemia | NCT00022451 | Leukemia | tipifarnib | - 21 Years | National Institutes of Health Clinical Center (CC) | |
| Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia | NCT01020539 | Acute Myelogeno... Myelodysplastic... Juvenile Myelom... | Fludarabine Busulfan GVHD Prophylaxi... Gemtuzumab Ozog... Anti-Thymocyte ... Isotretinoin | 1 Month - 30 Years | Columbia University | |
| Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML) | NCT00167219 | Juvenile Myelom... | Stem Cell Trans... Preparative Reg... | - 18 Years | Masonic Cancer Center, University of Minnesota | |
| Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia | NCT01020539 | Acute Myelogeno... Myelodysplastic... Juvenile Myelom... | Fludarabine Busulfan GVHD Prophylaxi... Gemtuzumab Ozog... Anti-Thymocyte ... Isotretinoin | 1 Month - 30 Years | Columbia University | |
| Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation | NCT00609739 | Leukemia | cyclosporine cytarabine filgrastim methotrexate methylprednisol... mitoxantrone hy... allogeneic bone... umbilical cord ... Cis-Retinoic ac... | - 18 Years | Masonic Cancer Center, University of Minnesota | |
| Study of Metabolic Syndrome in Adolescent and Young Adult Survivors of Childhood Leukemia Who Have Undergone Stem Cell Transplant | NCT00920842 | Cardiovascular ... Leukemia Long-term Effec... Metabolic Syndr... | 9 Years - 21 Years | Fred Hutchinson Cancer Center | ||
| T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant | NCT01621477 | Acute Lymphobla... Acute Myelocyti... Chronic Myelocy... Juvenile Myelom... Myelodysplastic... Hodgkin or Non-... Sarcoma, Myeloi... | clofarabine cytarabine busulfan Plerixafor cyclophosphamid... antithymocyte g... stem cells Tacrolimus mycophenolate m... | - 21 Years | St. Jude Children's Research Hospital | |
| Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML | NCT00669890 | Acute Myeloid L... Juvenile Myelom... Myelodysplastic... | Gemtuzumab Ozog... Busulfan Cyclophosphamid... Thymoglobulin Tacrolimus Mycophenolate M... Methotrexate | - 30 Years | New York Medical College | |
| Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis | NCT05515029 | Acute Lymphobla... Myeloblastic Le... Biphenotypic Ac... Malignant Lymph... Myelodysplastic... Juvenile Myelom... | GVHD prevention... | 1 Day - 21 Years | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | |
| Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies | NCT00619879 | Leukemia, Myelo... Leukemia, Lymph... Leukemia, Myelo... Myeloproliferat... Lymphoma, Malig... | Myeloablative C... Myeloablative C... Hematopoietic P... CNS radiation t... | - 21 Years | Ann & Robert H Lurie Children's Hospital of Chicago | |
| Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases | NCT00309842 | Acute Myeloid L... Acute Lymphocyt... Chronic Myeloge... Myelofibrosis MDS Refractory Anem... Chronic Lymphoc... Prolymphocytic ... Non-Hodgkin's L... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | filgrastim cyclophosphamid... cyclosporine fludarabine pho... mycophenolate m... umbilical cord ... total-body irra... | - 55 Years | Masonic Cancer Center, University of Minnesota | |
| Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia | NCT03190915 | Juvenile Myelom... Neurofibromatos... | Bone Marrow Asp... Trametinib | 1 Month - 21 Years | National Cancer Institute (NCI) | |
| Study for Epidemiology and Characterization of Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leucemia (JMML) in Childhood | NCT00662090 | Myelodysplastic... Juvenile Myelom... | - 215 Months | University Hospital Freiburg | ||
| A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation | NCT04024761 | Acute Myeloid L... Myelodysplastic... Myeloproliferat... Juvenile Myelom... | CIML NK Fludarabine Cyclophosphamid... | 12 Years - | Dana-Farber Cancer Institute | |
| Decision Making About Participating in Pharmacokinetic Studies in Patients Enrolled in a Phase I Treatment Clinical Trial | NCT00890435 | Brain and Centr... Leukemia Unspecified Adu... Unspecified Chi... | questionnaire a... psychosocial as... | 18 Years - | Children's Oncology Group | |
| Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia | NCT01445080 | Blastic Phase Childhood Acute... Childhood Chron... Childhood Solid... Chronic Myeloge... Juvenile Myelom... Philadelphia Ch... Recurrent Child... Recurrent Child... Recurrent Disea... | Laboratory Biom... Pharmacological... Sorafenib Tosyl... | 2 Years - 21 Years | National Cancer Institute (NCI) | |
| Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases | NCT00450450 | Childhood Acute... Childhood Acute... Childhood Chron... Childhood Myelo... Chronic Phase C... de Novo Myelody... Juvenile Myelom... Previously Trea... Recurrent Child... Secondary Myelo... | allogeneic bone... laboratory biom... filgrastim | - 21 Years | Children's Oncology Group | |
| Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies | NCT00143559 | Leukemia Acute Lymphobla... Acute Myeloid L... Chronic Myeloid... Juvenile Myelom... Myelodysplastic... Paroxysmal Noct... Hodgkin's Lymph... Non-Hodgkin Lym... | Systematic chem... Allogeneic stem... Miltenyi CliniM... | 2 Years - 21 Years | St. Jude Children's Research Hospital | |
| Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis | NCT05515029 | Acute Lymphobla... Myeloblastic Le... Biphenotypic Ac... Malignant Lymph... Myelodysplastic... Juvenile Myelom... | GVHD prevention... | 1 Day - 21 Years | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | |
| MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies | NCT05735717 | Hematologic Mal... Acute Leukemia Remission Acute Myeloid L... Acute Lymphobla... AML TP53 Intrachromosoma... Cytogenetic Abn... CNS Leukemia Minimal Residua... Myelodysplasia Juvenile Myelom... Somatic Mutatio... PTPN11 Gene Mut... N-RAS Gene Ampl... Neurofibromatos... NF1 Mutation CBL Gene Mutati... Monosomy 7 Chromosome Abno... Fetal Hemoglobi... | Fludarabine Busulfan Melphalan Rituximab Levetiracetam | - 60 Years | Masonic Cancer Center, University of Minnesota | |
| Decision Making About Participating in Pharmacokinetic Studies in Patients Enrolled in a Phase I Treatment Clinical Trial | NCT00890435 | Brain and Centr... Leukemia Unspecified Adu... Unspecified Chi... | questionnaire a... psychosocial as... | 18 Years - | Children's Oncology Group | |
| The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study | NCT04726241 | Acute Lymphobla... Acute Myeloid L... Acute Myeloid L... Juvenile Myelom... Mixed Phenotype... Myelodysplastic... Myelodysplastic... Myeloid Leukemi... | Biospecimen Col... | - 22 Years | LLS PedAL Initiative, LLC | |
| Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS) | NCT02564536 | Chronic Myelomo... Juvenile Myelom... Atypical Chroni... Myeloproliferat... Myelodysplastic... Myelofibrosis | Pacritinib Decitabine | 18 Years - | Washington University School of Medicine |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
